HeartWare to Report Financial Results for First Quarter of 2010

FRAMINGHAM, Mass. and Sydney, April 12, 2010 /PRNewswire via COMTEX/ -- HeartWare International, Inc. /quotes/comstock/15*!htwr/quotes/nls/htwr (HTWR 46.38, -0.61, -1.30%) will release financial results for the first quarter ended March 31, 2010 after the close of the U.S. markets on Monday, May 3, 2010.

A conference call with management is scheduled for 5:00 pm U.S. Eastern Time on Monday, May 3, 2010 (being 7:00 am Australian Eastern Standard Time on Tuesday, May 4, 2010) to discuss the Company’s financial results and to provide a corporate update. The call may be accessed by dialing 1-877-407-4018 five minutes prior to the scheduled start time and referencing “HeartWare.” For callers outside the United States, dial + 1-201-689-8471.

A live webcast of the call will also be available at the Company’s website (www.heartware.com) by selecting “HeartWare First Quarter Conference Call” under the section titled “Corporate Presentations” on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(R) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of a United States clinical trial for a bridge-to-transplant indication with enrollment completed in February 2010. For additional information, please visit the company’s website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information: Christopher Taylor HeartWare International, Inc. Email: ctaylor@heartwareinc.com Phone: +1 508 739 0864 SOURCE HeartWare International, Inc. Copyright (C) 2010 PR Newswire. All rights reserved

MORE ON THIS TOPIC